more

DaVita (DVA)

(Delayed Data from NYSE)

$138.57 USD

-2.88 (-2.04%)

Updated Jun 28, 2024 04:00 PM ET

After-Market: $138.52 -0.05 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.08%
2	Buy	17.91%
3	Hold	9.44%
4	Sell	5.10%
5	Strong Sell	2.55%
S&P	500	11.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5 2

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth B Momentum A VGM

Industry Rank:

Top 18% (45 out of 249)

Industry: Medical - Outpatient and Home Healthcare

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.

Top Ranked Momentum Stocks to Buy for July 26th

by Zacks Equity Research Published on July 26,2019

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, July 26th

DaVita HealthCare (DVA) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research Published on July 25,2019

DaVita HealthCare (DVA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

DVANegative Net Change

DVA vs. CHE: Which Stock Is the Better Value Option?

by Zacks Equity Research Published on July 25,2019

DVA vs. CHE: Which Stock Is the Better Value Option?

New Strong Buy Stocks for July 25th

by Tirthankar Chakraborty Published on July 25,2019

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday

Stock Market News For Jul 23, 2019

by Zacks Equity Research Published on July 23,2019

Markets ended in the green on Monday following a broad-based rally in the tech stocks.

DaVita (DVA) Announces Preliminary Q2 Results, View Upbeat

by Zacks Equity Research Published on July 23,2019

Management at DaVita (DVA) expects impressive contribution from calcimimetics in Q2.

UnitedHealth (UNH) Beats on Q2 Earnings, Guides Up for 2019

by Zacks Equity Research Published on July 18,2019

Strong segment performance, membership growth and cost control aid UnitedHealth's (UNH) Q2 results.

medical

UnitedHealth (UNH) to Report Q2 Earnings: What's in Store?

by Zacks Equity Research Published on July 16,2019

UnitedHealth's (UNH) second-quarter results are expected to be boosted by the revenue growth at UnitedHealthcare and Optum segments and increasing membership.

medical

The Zacks Analyst Blog Highlights: DaVita, Fresenius, Baxter, Amgen and CVS

by Zacks Equity Research Published on July 12,2019

The Zacks Analyst Blog Highlights: DaVita, Fresenius, Baxter, Amgen and CVS

medical

Trump's Order on Kidney Care Lifts These Dialysis Stocks

by Tirthankar Chakraborty Published on July 11,2019

Dialysis stocks move north after Trump signs an executive order designed to reform the nation's kidney treatment industry.

Trump's Kidney Disease Executive Order May Boost This Health Stock, Tank Others

by Mitchell Moore Published on July 10,2019

President Trump signed an executive order Wednesday that will encourage an increase in kidney transplants. This transplant diagnostic company stands to grow significantly, while dialysis companies will take a hit.

medical

UnitedHealth (UNH) Closes DaVita Unit Buy, Expands OptumCare

by Zacks Equity Research Published on June 26,2019

UnitedHealth's (UNH) purchase of DaVita Medical Group will likely aid the growth of OptumHealth, which is targeting double-digit percentage revenue long-term growth.

medical

DaVita Divests DMG to Optum, Boosts Kidney Care Services

by Zacks Equity Research Published on June 20,2019

The divestment of DMG boosts DaVita's (DVA) core Kidney Care business.

medical

Why Is DaVita HealthCare (DVA) Down 9.9% Since Last Earnings Report?

by Zacks Equity Research Published on June 06,2019

DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

DVANegative Net Change

Here's Why You Should Retain DaVita (DVA) in Your Portfolio

by Zacks Equity Research Published on May 16,2019

DaVita (DVA) is gaining steadily from expansion in international markets, strong demand in dialysis services and prudent acquisitions. However, divestment of DMG segment might lower cash flows.

medical

DaVita (DVA) Earnings and Revenues Miss Estimates in Q1

by Zacks Equity Research Published on May 08,2019

DaVita (DVA) gains from international revenues in Q1.

DaVita HealthCare (DVA) Q1 Earnings and Revenues Miss Estimates

by Zacks Equity Research Published on May 07,2019

DaVita HealthCare (DVA) delivered earnings and revenue surprises of -4.21% and -2.74%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

DVANegative Net Change

What's in the Cards for DaVita (DVA) This Earnings Season?

by Zacks Equity Research Published on May 02,2019

Better-than-expected performance at Kidney Care, strategic buyouts and international expansion might aid DaVita (DVA) in Q1. However, integration risks might be a dampener.

Analysts Estimate DaVita HealthCare (DVA) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research Published on April 30,2019

DaVita HealthCare (DVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

DVANegative Net Change

Analysts Estimate DaVita HealthCare (DVA) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research Published on April 25,2019

DaVita HealthCare (DVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

DVANegative Net Change

Here's Why You Should Hold on to DaVita (DVA) Stock Now

by Zacks Equity Research Published on April 10,2019

DaVita (DVA) is gaining steadily from expansion in international markets, strong demand in dialysis services and prudent acquisitions. However, rising expenses remain a dampener.